Genomic Assays Impact Treatment Decisions in Patients With ER+ Breast Cancer
Matthew P. Goetz, MD, discusses how genomic assays can help identify patients with ER–positive breast cancer who will benefit from the addition of chemotherapy to endocrine therapy.
Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses how genomic assays can help identify patients with estrogen receptor (ER)positive breast cancer who will benefit from the addition of chemotherapy to endocrine therapy.
There are a number of considerations when selecting a genomic assay for these patients, says Goetz. For the past 10 to 15 years, the focus has been on identifying patients with ER-positive disease who could do well with endocrine therapy alone versus those who need the addition of chemotherapy to treatment. A number of genomic assays are now in development to help identify those patients that can be de-escalated from chemotherapy.
Over the last few years, a number of different clinical trials have helped in identifying which genomic assays are most useful in this setting, and recent data have confirmed the utility of these assays in patient selection. Data suggest that the most useful assay is the Oncotype DX test, which assigns patients a recurrence score.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
